Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gebasaxturev - Viralytics

Next Previous
X
Search
Drug Profile

Gebasaxturev - Viralytics

Alternative Names: CAV21; Cavatak; Coxsackievirus A21; CVA 21; V 937

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViroTarg
  • Developer Merck & Co; Viralytics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action CD55 antigen inhibitors; Cell death stimulants; Intercellular adhesion molecule-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • No development reported Bladder cancer; Chronic lymphocytic leukaemia; Glioma; Lung cancer; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Uveal melanoma

Most Recent Events

  • 20 Mar 2024 Merck & Co terminates a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Canada, France, Japan, Israel, Italy, Germany, Hungary, Norway, Peru, Poland, Portugal, Spain, USA, Taiwan (Intratumoural), due to business reasons (EudraCT2020-001908-42) (NCT04521621)
  • 01 Mar 2024 Merck & Co terminated a phase II trial in Malignant melanoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Australia, Chile, France, Germany, Israel, Italy, Norway, Spain, South Korea, South Africa, New Zealand, the UK, and the US (Intratumoural) (IV) due to business reasons (NCT04152863)
  • 25 Jul 2023 Merck & Co completes a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Canada, France, Japan, Israel, Italy, Germany, Hungary, Norway, Peru, Poland, Portugal, Spain, USA, Taiwan (Intratumoural) (EudraCT2020-001908-42) (NCT04521621)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top